Schedule a Free Evaluation: 919-354-3775 contact@extivita.org
  • Facebook
  • Twitter
  • Instagram
  • RSS
  • Vimeo
  • Linkedin
  • YouTube
  • Facebook
  • Twitter
  • Instagram
  • RSS
  • Vimeo
  • Linkedin
  • YouTube
  • Patient Portal
  • Register
  • Contact
Extivita - Hyperbaric Oxygen Therapy - Durham, NC
  • Home
  • Conditions We Treat
  • Therapies
    • Hyperbaric Oxygen
    • IV Therapy
    • Neurofeedback
    • PEMF
    • Supplements
    • Longevity Challenge
  • Testimonials
  • About
    • News
    • Research
    • Extivita RTP Team
Select Page

Management of bisphosphonate-related osteonecrosis of the jaw: a literature review.

by Extivita | Jan 6, 2015 | Myeloma

Abstract: Osteonecrosis of the jaw (ONJ) is a serious side effect of bisphosphonate use in patients with osteoporosis, Paget’s disease, hypercalcemia of malignancy, metastatic bone disease and multiple myeloma, although recently this complication has also been...

Necrotizing fasciitis as a rare complication of osteonecrosis of the jaw in a patient with multiple myeloma treated with lenalidomide: case report and review of the literature.

by Extivita | Nov 14, 2013 | Myeloma

Abstract: Bisphosphonates (BPs), potent inhibitors of osteoclast-mediated bone resorption, play a major role in the management of patients with multiple myeloma (MM). However, in the case of dental infections, they can lead to bisphosphonate related osteonecrosis of...

What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics.

by Extivita | Dec 22, 2011 | Myeloma

Abstract: This study tested hyperbaric oxygen (HBO) as an adjunct to surgery and antibiotics in the treatment of bisphosphonate-related osteonecrosis of the jaw (ONJ) and evaluated its effects on gingival healing, pain, and quality of life. The investigators...

Evolution of bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma and Waldenstrom’s macroglobulinemia: a retrospective multicentric study.

by Extivita | Jun 27, 2011 | Myeloma

Abstract: Bisphosphonates (BPs) are used intravenously to treat cancer-related conditions for the prevention of pathological fractures. Osteonecrosis of the jaw (BRONJ) is a rare complication reported in 4-15% of patients. We studied, retrospectively, 55 patients with...

Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) therapy. A critical review.

by Extivita | Apr 3, 2010 | Myeloma

Abstract: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is an area of uncovered bone in the maxillo-facial region that did not heal within 8 weeks after identification by health care provider, in a patient who was receiving or had been exposed to...

[New development in bisphosphonate treatment. Bisphosphonate therapy and osteonecrosis of the jaws].

by Extivita | Jan 6, 2009 | Myeloma

Abstract: Bisphosphonates (BP) have clinically been used as a highly effective drug in the treatment of hypercalcemia of malignancy, multiple myeloma, skeletal events associated with metastatic breast cancer and prostate cancer, and osteoporosis. Despite these...
« Older Entries

Search News

 

Archives

 

Contact Us

     

     

     

     

    Professional Memberships

    HBOT Member Logo
    • About Extivita
    • Extivita RTP Team
    • Patient Portal
    • Register
    • Contact
    • Policies
    • Facebook
    • Twitter
    • Instagram
    • RSS
    © 2015-2021 Extivita, LLC
    Hyperbaric Oxygen Therapy (HBOT), Nutritional IV, Neurofeedback Clinic located in Research Triangle Park, North Carolina (RTP, Raleigh, Durham, Chapel Hill).